Table 1.
Recent clinical trials of immunotherapy for SCLC
| Patients | Clinical trial | Agent | ORS | 1‐year OS | OS (m) |
Trial state | Phase |
|---|---|---|---|---|---|---|---|
| Second line (ED) | Checkmate032 | Nivo Nivo + IPI |
10% 23% |
27% 40% |
4.1 7.8 |
Closed | I/II |
| KEYNOTE028 | Pemb | 33% | 33.7% | 9.7 | Closed | I | |
| PCD4989g | Atezo | 6% | 5.9 | Closed | I | ||
| CheckMate331 | Nivo vs. Topotecan or Amrubicin |
Enrolling | III | ||||
| NCT02963090 | Pemb vs. Topotecan |
Enrolling | II | ||||
| MISP‐MK3475 | Pemb + paclitaxel | Enrolling | II | ||||
| NCT03059667 | Atezo vs. chemotherapy |
Enrolling | II | ||||
| NCT02701400 | Radiotherapy + Treme + durva vs. treme, + durva | Enrolling | II | ||||
| NCT02937818 | Durva + Treme vs. AZD1775 + carboplatin |
Enrolling | II | ||||
| MEDIOLA | Olaparib (PARP) + Durva | Enrolling | I/II | ||||
| Maintenance (ES) | NCT02359019 | Pemb | 9.2 | Closed | II | ||
| CheckMate451 | Nivo | Enrolling | III | ||||
| First line (ES) | NCT02402920 | Pemb + Radio‐chemotherapy | Enrolling | I | |||
| KEYNOTE‐011 | Pemb + EC | Enrolling | I | ||||
| REACTION | Pemb + chemotherapy vs. chemotherapy |
Enrolling | II | ||||
| KEYNOTE‐604 | Pemb + EP vs. placebo + EP |
Enrolling | III | ||||
| Impower133 | Atezo + EC vs. placebo + EC |
Enrolling | III | ||||
| NCT02748889 | Atezo + chemotherapy vs. chemotherapy |
Enrolling | II | ||||
| NCT03041311 | Trilaciclib + EC + Atezo vs. Placebo + EC + Atezo |
Enrolling | II | ||||
| Caspian | Durva + treme + EP vs. Durva + EP vs.EP |
Enrolling | III |
Atezo, atezolizumab; durva, durvalumab; EC, etoposide and carboplatin; EP, etoposide and cisplatin; ES, extensive disease; IPI, ipilimumab; nivo, nivolumab; OR, odds ratio; OS, overall survival; pemb, pembrolizumab; SCLC, small‐cell lung cancer; treme, tremelimumab.